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ABSTRACT Hypoxia, as occurs during tissue isch-
emia, tips the natural anticoagulant/procoagulant bal-
ance of the endovascular wall to favor activation of
coagulation. Plasminogen activator inhibitor-1 (PAI-1)
is an important factor suppressing fibrinolysis under
conditions of low oxygen tension. We previously re-
ported that hypoxia induced PAI-1 mRNA and antigen
expression in murine macrophages secondary to in-
creased de novo transcription as well as increased
mRNA stability. We now show in RAW264.7 murine
macrophages that the transcription factors early growth
response gene-1 (Egr-1), hypoxia-inducible factor-1
(HIF-1), and CCAAT/enhancer binding protein 
(C/EBP) are quickly activated in hypoxia and are
responsible for transcription and expression of PAI-1.
Murine PAI-1 promoter constructs, including Egr, HIF-
1, and/or C/EBP binding sites, were transfected
into RAW 264.7 murine macrophages. To identify the
relative importance of each of these putative hypoxia-
responsive elements, cells were exposed to normobaric
hypoxia, and transcriptional activity was recorded. At
16 h of hypoxic exposure, murine PAI-1 promoter
deletion constructs that included Egr, HIF-1, and/or
C/EBP binding sites demonstrated increased tran-
scriptional activity. Mutation of each of these three
murine PAI-1 promoter sites (or a combination of
them) resulted in a marked reduction in hypoxia sensi-
tivity as detected by transcriptional analysis. Functional
data obtained using 32P-labeled Egr, HIF-1 response
element (HRE), and C/EBP oligonucleotides re-
vealed induction of DNA binding activity in nuclear
extracts from hypoxic RAW cells, with supershift anal-
ysis confirming activation of Egr-1, HIF-1, or
C/EBP. ChIP analysis confirmed the authenticity of
these interactions as each of these transcription factors
binds to chromatin under hypoxic conditions. Further,
the induction of PAI-1 by Egr-1, HIF-1, or C/EBP
was replicated in primary peritoneal macrophages.
These data suggest that although HIF-1 appears to
dominate the PAI-1 transcriptional response in hyp-
oxia, Egr-1 and C/EBP greatly augment this response
and can do so independent of HIF-1 or each other.
These studies are relevant to ischemic up-regulation
of the PAI-1 gene and consequent accrual of micro-
vascular thrombus under ischemic conditions.—Liao,
H., Hyman, M. C., Lawrence, D. A., Pinsky, D. J.
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When the steady flow of blood to a vital tissue is
interrupted, even transiently, tissue oxygen concentra-
tions plummet. The lack of oxygen triggers a charac-
teristic pattern of responses that occur at either the
tissue level (such as vasomotion) or at the cellular level.
When oxygen is scarce, the phenotype of the endovas-
cular wall changes markedly. Normally, an anticoagu-
lant surface, new proteins are expressed by cells of the
endovascular wall that fundamentally alter its proper-
ties, resulting in a prothrombotic phenotype (1–3). A
number of different cell types participate in this phe-
notypic shift, including endothelial cells (in which NO
bioavailability and thrombomodulin levels decline),
vascular smooth muscle cells (which are driven to
express tissue factor), and mononuclear phagocytes
(MPs) (3, 4), which express both tissue factor and
plasminogen activator inhibitor-1 (PAI-1), thereby si-
multaneously triggering formation of fibrin and retard-
ing its degradation. Because oxygen scarcity also drives
expression of chemotactic factors and expression of
leukocyte adhesion receptors, MPs accumulate in isch-
emic vessels and tissue, thereby amplifying the cycle
leading to thrombus accretion. Given their key roles in
hypoxia-driven thrombosis, it is essential to understand
operative mechanisms in MPs that contribute to their
prothrombtic phenotypic shift (5).
Plasminogen activator/inhibitor-1 (PAI-1), a 50 kDa
protein that is the main circulating inhibitor of plas-
minogen activation (and therefore the chief inhibitor
of fibrinolysis), is strongly expressed by MPs exposed in
vitro to pO2s of 14–16 Torr. The importance of PAI-1
induction by hypoxia in the development of intravascu-
lar thrombosis is underscored by the observation that
fibrin accrual increases markedly in mice placed in a
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normobaric hypoxic environment and that fibrin ac-
crual is substantially diminished in hypoxia-exposed
PAI-1 gene null mice (5). It appears that the predom-
inant mechanism by which hypoxia leads to PAI-1
induction is transcriptionally driven, as nuclear run-on
analysis of hypoxic MPs reveals a de novo increase in
nascent PAI-1 mRNA (5). Although the PAI-1 promoter
has a recognized HIF-1 motif (6–9), the importance
of this motif in driving hypoxia-induced expression of
PAI-1 in hypoxic MPs is not known (10, 11). Further-
more, the relative contribution of other HIF-1-inde-
pendent, hypoxia-responsive elements in the PAI-1
promoter, such as early growth response-1 (Egr-1), is
unknown. Egr-1 is an immediate-early gene that en-
codes a nuclear phosphoprotein containing three zinc
finger elements; these bind target GC-rich elements
with a consensus sequence of 5-GCG(T/G)GGGCG-3
in the promoter of many different genes, thereby
regulating transcription (12–16). PAI-1 is one such
gene that has an Egr-1 site in its promoter region.
Others included the hypoxia-responsive genes tissue
factor, various growth factors, cytokines/chemokines,
and adhesion receptors. Even vascular endothelial
growth factor (VEGF), a classical HIF-1 responsive
gene, has hypoxia-responsive Egr-1 elements in its
promoter region (17). Egr-1 is rapidly activated and
expressed in hypoxia, both in vitro and in vivo, and is
responsible for transcription and expression of a di-
verse array of effector genes in hypoxic/ischemic lungs
(18–25).
Hypoxia-inducible factor 1 (HIF-1) is another DNA
binding protein comprised of a heterodimer between
two basic helix-loop-helix transcription factors: HIF-1
and the ARNT (aryl hydrocarbon receptor nuclear
translocator) (26). When cells are exposed to oxygen
concentration considered to be normal (normoxia),
newly synthesized HIF-1 undergoes rapid degrada-
tion. This degradation is mediated by prolyl hydroxy-
lases (27, 28), a family of dioxygenase enzymes that
catalyze hydroxylation of conserved proline residues
(Pro402 and Pro564) in the critical oxygen-dependent
degradation domain of HIF-1 (29). Hydroxylated
HIF-1 is then recognized by von Hippel-Lindau pro-
tein (a component of the E3 ubiquitin ligase complex),
which targets it for subsequent proteasomal degrada-
tion (30–32). In this manner, normal oxygen concen-
trations ensure tonic degradation of this key compo-
nent of the active HIF-1 heterodimer, ensuring
nonactivity at multiple gene promoter sites. As the
activity of the prolyl hydroxylases depend on O2 con-
centration, under prevailing hypoxic conditions, pro-
line hydroxylation is inhibited, eliminating binding
between HIF-1 and the von Hippel–Lindau protein.
This causes HIF-1 to stabilize, reflected by increased
half-life, accumulation, and migration to the nucleus,
where the HIF-1-ARNT complex interacts with hyp-
oxia-responsive elements (HREs) in transcriptional reg-
ulatory regions of multiple target genes (33). Many of
these HIF-1-induced genes, such as those encoding
for glycolytic enzymes, growth factors, and vasoactive
peptides, share the common feature of blunting tissue
damage in situations of oxygen scarcity.
CCAAT /enhancer binding proteins (C/EBPs) com-
prise a family of transcription factors that each contain
a highly conserved, basic C-terminal leucine zipper that
mediates dimerization and DNA binding. There are at
least six known members of the C/EBP family that have
been isolated and characterized so far, including
C/EBP-, -, -, -, -ε, and - (34). C/EBP is a basic
region leucine zipper (bZIP) DNA binding protein that
recognizes the symmetric sequences ATTGCGCAAT
and ATGAGTCAT, respectively (35). Binding occurs
between target gene promoter DNA and either C/EBP
homodimers or heterodimers. Although each family
member stimulates different portfolios of genes, the
focus in the current work is on C/EBP, which has
been regarded mainly as a regulator of cell growth and
proliferation (36–40), and perhaps of inflammation
(41).
To investigate the mechanism by which hypoxia
elicits PAI-1 induction, deletion constructs fused to the
luciferase reporter gene were transiently expressed in
RAW cells. Measurement of luciferase activities, as well
as EMSA analysis of transcription factor binding sites
and the relative effect of site-specific mutations, enable
us to identify three functional regulatory elements—
Egr-1, HIF-1, and C/EBP—in the murine PAI-1
promoter region (Fig. 1A) that regulate the response to
hypoxia.
MATERIALS AND METHODS
Cell culture and hypoxic treatment
RAW cells (a transformed murine macrophage cell line) were
obtained from the American Type Culture Collection (ATCC;
Rockville, MD, USA) and grown in RPMI 1640 medium with
10% FCS (Invitrogen, Carlsbad, CA, USA) and penicillin-
streptomycin (50 U/ml and 5 g/ml, respectively). When
RAW cells achieved confluence, experiments were performed
by washing cells three times with serum-free medium, then
placing them in either a standard cell culture incubator
(37°C, 5% CO2) or a similar incubator within an hypoxia
chamber. This environmental chamber (BioSpherix, Red-
field, NY, USA) provides a controlled temperature (37°C)
and a humidified anoxic atmosphere, resulting in an oxygen
tension in the culture medium of 14–18 Torr.
Isolation of a mouse PAI-1 genomic clone
A 1278 bp fragment containing 1155 bp of 5-flanking
(–1155) and 123 bp of the untranslated first exon (123) of
mouse PAI-1 was isolated using a polymerase chain reaction
(PCR) on RAW cell’s total genomic DNA. The primers (5
primer, 5-CCTAACTTCCATTCCCAACACCCACGAC-3; 3
primer, 5-GCCTTGTGATTGGCTCTTGTTGGCTGTC-3)
were designed by analysis of the sequence of the mouse PAI-1
gene, 5 flank (GenBank accession #M33961) (42). The 1279
bp insert was subcloned into pGEM-T vector (Promega,
Madison, WI, USA) using the pGEM-T Easy Vector System
(Promega), and sequenced in both directions to confirm
identity.
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Construction of mouse PAI-1 promoter-luciferase reporter
plasmids and site-directed mutagenesis
PCR was used to amplify mouse PAI-1 promoter-luciferase
reporter constructs representing 5-deleted PAI-1 upstream
sequences, and these PCR products were subcloned into the
pGL3 basic vector (Promega). In these PCRs, the PAI-1
genomic clone (described above) was used as a template. The
5-deletion constructs of the PAI-1 promoter represent –287
to  50 (pGLPAI.Luc/287), –194 to  50 (pGLPAI.Luc/
194), –162 to  50 (pGLPAI.Luc/162), –67 to  50 (pGL-
PAI.Luc/67), 	-291 to –183 (pGLPAI.Luc/CEBP, containing
C/EBP binding sites only), 	-201 to –144 (pGLPAI.Luc/
HRE, containing HIF-1 binding sites only), and 	-162 to –61
(pGLPAI.Luc/EGR, containing Egr binding sites only) (Fig.
1B). For mutants, oligonucleotides used for priming were
synthesized based on sequences of the 5-flanking region of
the mouse PAI-1 gene. The site-directed mutants of the
pGLPAI.Luc/Emut, pGLPAI.Luc/Hmut, pGLPAI.Luc/
Cmut, GLPAI.Luc/EHmut, pGLPAI.Luc/ECmut, pGL-
PAI.Luc/HCmut, and pGLPAI.Luc/EHCmut constructs (Fig.
2) were generated using QuikChange site-directed mutagen-
esis kits (Stratagene, La Jolla, CA, USA). In these PCRs, the
5-deletion constructs, representing –287/50 (337 bp) of
the PAI-1 gene, were used as a template. The mutated
priming oligonucleotides represented overlapping sense and
antisense sequences of the mutant site that amplified the
entire pGL3 plasmid and insert. The mutated primer for each
transcription factor binding site in the –287/50 fragment
are shown as follows (target regions are underlined and
alterations are indicated by boldface):
EGR mutant primer for pGLPAI.Luc/Emut, GLPAI.Luc/
EHmut GLPAI.Luc/ECmut, and pGLPAI.Luc/EHCmut
5-GAGGGAGGGAGGGATAGGGAGAGGGGGCAGGG-3;
HRE mutant primer for pGLPAI.Luc/Hmut, GLPAI.Luc/
Ehmut GLPAI.Luc/Hcmut and pGLPAI.Luc/EHCmut 5-
CATGCCCTTCACACTATCACACACTATTCCCAGCAAGTCA-3;
C/EBP mutant primer for pGLPAI.Luc/Cmut, GLPAI.Luc/
ECmut GLPAI.Luc/HCmut and pGLPAI.Luc/EHCmut 5-
GGGAACCAGAGTGACTAGTCTTATCCCCCATGCCCTT-
CACACG-3. Forward and reverse DNA sequencing of inserts
Figure 2. Mutational analysis of hypoxia-responsive elements
of the PAI-1 promoter. Nucleotides sequence of the 5-
flanking region and 50 nucleotides of the first exon of the
mouse PAI-1 gene. The transcription start site is denoted as
 1. A potential Egr-1, two HRE, and one C/EBP binding
sites are underlined. Transient transfection of RAW cells
using pGL3PAI.Luc/287 (consensus Egr, HRE, and C/EBP
WT sequence) or mutationally inactivated sequence, pGL-
PAI.Luc/Emut (Egr), pGLPAI.Luc/Hmut (HIF-1), pGL-
PAI.Luc/Cmut (C/EBP), pGLPAI.Luc/Ehmut (EgrHIF-
1), pGLPAI.Luc/Ecmut (EgrC/EBP), pGLPAI.Luc/
Hcmut (HIF-1, C/EBP), and pGLPAI.Luc/EHCmut
(EgrHIF-1C/EBP), and pCMV/-galactosidase (In-
vitrogen) by the same procedure described in Fig. 1.
Figure 1. Hypoxia-inducible PAI-1 expression results from
transcriptional activation at EGR, HIF-1, and C/EBP site-
delete analysis of the PAI-1 promoter. (GenBank accession #
M33961) (42). A) The 5-flanking region of the mouse PAI-1
gene with its Egr, HRE, and C/EBP binding sites. Transient
cotransfection of RAW cells was performed using either
pGL3PAI.Luc/287, pGL3PAI.Luc/201, pGL3PAI.Luc/166,
or pGL3PAI.Luc/112, pGL3PAI.Luc/CEBP, pGL3PAI.Luc/
HRE, pGL3PAI.Luc/EGR, and pCMV/-galactosidase (In-
vitrogen). Cultures were transfected with each of the indi-
cated constructs using the SuperFect procedure (Qiagen),
then cells were exposed to normoxia or hypoxia (B). Lucif-
erase activities were then determined with a luciferase re-
porter assay system (Promega). Relative firefly luciferase
activity is normalized to control pCMV/-galactosidase activity.
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confirmed the sequences of all constructs employed for
transfection assays.
Construction of mouse Egr-1, HIF-1, and C/EBP
overexpression plasmids
The cDNA clones of mouse Egr-1, HIF-1, and C/EBP were
ordered from ATCC (Manassas, VA, USA). Egr-1 expression
vector (pEgr-1), HIF-1 expression vector (pHIF-1), and
C/EBP expression vector (pC/EBP) were constructed by
first using PCR to amplify the open reading frame (ORF) of
the Egr-1, HIF-1, and C/EBP cDNAs. The ORF of Egr-1
and HIF-1 cDNA was cloned into pcDNA3.1 (Invitrogen)
expression vectors. The ORF of C/EBP cDNA was cloned
into pMT/V5-His-TOPO (Invitrogen) heavy metal (zinc)-
inducible expression vector.
Transient transfections
RAW cells were cotransfected using SuperFect Transfection
Reagent (Qiagen, Valencia, CA, USA). The day before trans-
fection, RAW cells were plated on 12-well plates (Costar,
Corning, NY, USA) with 1 
 105 cells per well and grown in
RPMI 1640 (Invitrogen, Carlsbad, CA, USA) containing 10%
FCS (Invitrogen, Carlsbad, CA, USA). Cultures were incu-
bated at 37°C in a humidified atmosphere containing 5%
CO2 until they reached 50–80% confluence. The cells were
cotransfected using 0.75 g of PAI-1 promoter-pGL3 reporter
plasmid and 0.75 g of control plasmid, pCMV/-galactosi-
dase, which served as an internal control to normalize trans-
fection efficiency, as well as 7.5 l of SuperFect Transfection
Reagent in 75 l of serum-free RPMI 1640 medium. This was
followed by incubation at room temperature for 10 min, after
which the complexes were mixed with 0.4 ml of RPMI 1640
medium with 10% FBS. After incubating at 37°C and 5% CO2
for 3 h, the cells were washed three times with HBSS
(Invitrogen), then incubated with RPMI with 10% FBS. After
30 h incubation, the cell medium was changed to RPMI 1640,
then the cells were placed in either a standard cell culture
incubator (37°C, 5% CO2) or a similar incubator within the
hypoxia chamber for 16 h. Luciferase reporter assays were
performed using a Luciferase reporter assay system (Pro-
mega). Transfected cells were washed twice with cold PBS,
then harvested, lysed, and assayed for luciferase activity by a
VICTOR LIGHT luminometer (Perkin-Elmer, Boston, MA,
USA). -Galactosidase enzyme activity was measured using
-galactosidase enzyme assay system (Promega). Fifty micro-
liters of the sample was mixed with 50 l of 2
 buffer
containing 200 mM of sodium phosphate pH 7.3, 2 mM of
MgCl2, 100 mM of -mercaptoethanol, and 1.33 mg/ml of
o-nitrophenyl--galactopyranoside in a 96-well plate. After
incubation for 1 h at 37°C, the absorbances of the samples
were read at 420 nm in the VersaMax Tunable Microplate
Reader (Molecular Devices, Sunnyvale, CA, USA).
For the overexpression experiments, RAW cells were co-
transfected with 0.25 g of luciferase reporter plasmid
(pGL3PAI.Luc/287 or pGL3 basic control vector), 0.5 g of
pCMV/-galactosidase vector, and one, two, or all three
overexpression constructs (pEgr-1, pHIF-1, and/or pC/
EBP, 0.25 g/each construct). In these experiments the
total transfected DNA was 1.5 g/well consisting of the
overexpression vectors (0.25 g/vector), the balance being
comprised of control vectors (pcDNA3.1 for pEgr-1 and
pHIF-1, pMT for pC/EBP) as needed (see Fig. 10). The
method of transfection and report assay is described above.
Murine peritoneal macrophage isolation and transfection
Peritoneal macrophages were isolated as described previously
(43). In brief, 10-wk-old male C57Bl6/J mice were injected
with 1.0 ml of a 5% thioglycollate solution (BD, Franklin
Lakes, NJ, USA) i.p.. Four days later macrophages were
isolated by peritoneal lavage in ice-cold PBS. Red blood cells
were then lysed using a 0.15 M NH4Cl lysing solution before
plating at a concentration of 1 
 106 cells per well in 12-well
plates. After 24 h, the cells were transfected with 0.5 g/well
of overexpression plasmid (pEgr-1, pHIF-1, or pCEBP) and
1.5 l/well of Fugene 6 Transfection Reagent (Roche, Indi-
anapolis, IN, USA). While incubating the transfected cells in
hypoxia or normoxia, cells transfected with pC/EBP or pMT
were simultaneously incubated with 50 M of ZnCl2 to induce
C/EBP protein expression. Total RNA was then isolated
from the transfected murine peritoneal macrophage cells
using Total RNA Easy Kits (Qiagen); RT-qPCR was used to
assay levels of PAI-1, Egr-1, HIF-1, and C/EBP mRNA.
Quantitative RT-PCR
RAW cell were transfected with the overexpression constructs
(pEgr-1, pHIF-1, or pCEBP) to induce Egr-1, HIF-1, or
C/EBP protein expression, respectively. The empty vectors
(pCDNA3.1 for pEgr-1 and pHIF-1 or pMT vector for
pC/EBP) were used as control. RAW cells were plated onto
6-well plates (Costar, Corning, NY, USA). After RAW cells
reached 80% confluence, the cells were transfected using 2
g of expression or control vectors and 10 l of Superfect
Transfection Reagent (Qiagen). After 24 h of transfection,
the cells were incubated in hypoxic or normoxic conditions
for the indicated durations. Total RNA was then isolated from
the transfected RAW cells by using Trizol reagent (Invitrogen,
Carlsbad, CA, USA), and RT-qPCR was used to assay level of
PAI-1, Egr-1, HIF-1, and C/EBP mRNA. Real-time PCR
assay was carried out with the 7000 Sequence Detection
System (Applied Biosystems, Foster City, CA, USA) using
One-Step RT-polymerase chain reaction (RT-PCR) Master
Mix (Applied Biosystems) according to the manufacturer’s
instruction. The primers and probes sets were purchased
from Applied Biosystems. All RT-qPCRs were done in tripli-
cate. Hypoxic up-regulation of PAI-1, Egr-1, HIF-1, C/EBP
mRNA was normalized to -actin levels and reported as
relative fold increase compared with normoxia, determined
by the 2–		Ct method (44, 45).
Gel shift assay
Nuclear extracts were prepared by the procedure of Dignam
et al. (46) from RAW cells after exposure to hypoxic or
normoxic (control) conditions. Complementary reverse ori-
entation oligonucleotide probes were synthesized by Invitro-
gen and annealed by suspending in TE buffer, heating to
90°C for 5 min, followed by cooling at room temperature for
1 h. Strand sequences were as follows:
EGR: (–151/–127) 5-GGGAGGGAGGGAGGGAGGGG-
GAGAG-3,
5-CTCTCCCCCTCCCTCCCTCCCTCCC-3
HRE 1&2:(–189/–151) 5-CCCTTCACACGTACACA-
CACGTGTCCCAGCAAGTCACTG-3
5-CAGTGACTTGCTGGGACACGTGTGTGTACGTGTG-
AAGGG-3
C/EBP: (–220/–193), 5-GGAACCAGGGTTTGCTCAAT-
TATCCCCC-3,
5-GGGGGATAATTGAGCAAACCCTGGTTCC-3.
In each case, double-stranded oligonucleotide probes were
5 end-labeled with [-32P]ATP (3000 Ci/mmol, Amersham,
Arlington Heights, IL, USA) by using T4 polynucleotide
kinase (Promega). The labeled probe was incubated with 10
g of RAW cell nuclear extract at room temperature for 30
min (for Egr-1 and C/EBP) and at 4°C for Hif-1. For
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competition studies, a 100-fold molar excess of one of the
above unlabeled double-stranded probes was employed. Sam-
ples were loaded onto nondenaturing (6%) polyacrylamide
gels that had been subjected to an electrophoretic voltage
(100 V) for 20 min prior to loading. Electrophoresis was
performed for 1.5–2 h at 200V at room temperature (for
Egr-1 and C/EBP) and at 4°C for Hif-1 (because of the
lability of Hif-1). The gels were dried and subjected to
autoradiography overnight at –80°C. Gel supershifts were
performed as described above, except that before incubation
of oligonucleotide probe with nuclear extracts, 3 l of
anti-EGR-1, C/EBP SuperShift antibody (Santa Cruz Bio-
technology, Santa Cruz, CA, USA), or anti-HIF-1 IgG
(Novus, Littleton, CO, USA), was added to the nuclear extract
and incubated for 30 min at room temperature (for Egr-1 and
C/EBP) and at 4°C for HIF-1.
Western blot assay
Fifty micrograms of nuclear protein (prepared as described
above) was added to 4
 sample buffer and 10
 reducing
agent (Invitrogen, Carlsbad, CA, USA), boiled for 3 min,
separated by 10% SDS-PAGE, and electrophoretically trans-
ferred onto nitrocellulose membranes (Invitrogen). The
membranes were incubated with anti-Egr-1 antibody, anti-C/
EBP (Santa Cruz Biotechnology), or anti-HIF-1 (Novus,
Littleton, CO, USA) and autoradiographed using the en-
hanced chemiluminescence (ECL) method (ECL detection
system, Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Chromatin imunoprecipitation (ChIP) assay
The ChIP assay was performed using an EZ ChIPTM Chroma-
tin Immunoprecipitation Kit (Upstate Biotechnology, Char-
lottesville, VA, USA). RAW cells were cross-linked at 37°C for
10 min in 1% formaldehyde. Cells were then sonicated in lysis
buffer (1% SDS, 10 mM EDTA, 50 mM Tris pH 8.0, 1 mM
phenylmethylsulfonyl fluoride, 1 g/ml aprotinin, 1 g/ml
leupeptin, 1 g/ml pepstatin A) 10 times for 15 pulses at 30%
output at 4°C. The supernatant was divided into three tubes
for subsequent immunoprecipitation. Samples were pre-
cleared in i.p. buffer (0.01% SDS, 1.1% Triton, 1.2 mM
EDTA, 16.7 mM Tris pH 8.1, 167 mM NaCl, 1 mM phenyl-
methylsulfonyl fluoride, 1 g/ml aprotinin, 1 g/ml leupep-
tin, 1 g/ml pepstatin A) and added to protein A Sepharose
beads. The mixture was placed on a rotator for 1 h at 4°C,
after which beads were spun out and discarded (this step was
to clear the mixture of excess IgG). To the supernatant, 5 g
of anti-Egr-1, HIF1, C/EBP antibody (Santa Cruz), or
rabbit IgG was then added and the mixture was placed on a
rotator for 16 h at 4°C. Immunoprecipitates were recovered
by adding protein A Sepharose beads that were washed for 5
min with low salt immune complex wash buffer (0.1% SDS,
1% Triton, 2 mM EDTA, 20 mM Tris pH 8.1, and 150 mM
NaCl) for 5 min with high-salt immune complex wash buffer
(0.1% SDS, 1% Triton, 2 mM EDTA, 20 mM Tris pH 8.1, and
500 mM NaCl), 5 min with LiCl immune complex wash buffer
(0.25 M LiCl, 1% Nonidet P-40, 1% nadeoxycholate, 1 mM
EDTA, and 10 mM Tris pH 8.1), and twice for 3 min with TE
buffer (10 mM Tris pH 8.0 and 1 mM EDTA pH8.0). Immune
complexes were eluted during rotation with 1% SDS and 0.1
M NaHCO3 for a total of 30 min at room temperature.
Immunoprecipitates and inputs were reverse cross-linked
with 200 mM NaCl at 65°C for 4 h. Samples were then
incubated 1 h at 45°C with 10 mM EDTA, 40 mM Tris pH 6.5,
and 40 g/ml proteinase K. DNA was extracted by phenol/
chloroform extraction and ethanol precipitation. DNA was
amplified by PCR with a temperature cycle of 30 s at 94°C, 30 s
at 52°C, and 1 min at 68°C for 35 cycles. Primers used for PCR
correspond to the mouse PAI-1 promoter region (–280 to
123, 5 primer: 5-CCAGGGTTTGCTCAATTATC-3; 3
primer: 5-GCCTTGTGATTGGCTCTTGTTGGCTGTC-3).
Statistics
Statistical analysis was performed using ANOVA to detect
differences between groups, using Statview software. Differ-
ences were considered significant if P  0.05.
RESULTS
When mononuclear phagocytes are placed in an envi-
ronment in which oxygen is scarce, a number of gene
programs are activated that result in the expression of
new proteins that are either pathological or adapative,
depending on the context. One such protein of critical
importance to hemostasis and wound healing is plas-
minogen activator/inhibitor-1 (PAI-1), whose expres-
sion increases 10-fold in RAW macrophages placed in
an oxygen-scarce environment (16 Torr).
We previously reported (5, 47) that hypoxia induces
mouse PAI-1 mRNA and protein expression in the RAW
macrophage cell line. Hypoxia induces an 11-fold in-
duction of PAI-1 transcripts due to both increased de
novo transcription and increased mRNA stability com-
pared with normoxic PAI-1/ controls.
To characterize the mechanism by which PAI-1 tran-
scription in RAW cells is up-regulated by hypoxia, we
cloned a 337 bp genomic fragment that contains 287 bp
of 5-flanking region upstream of the mouse PAI-1 gene
(Fig. 1A). To delineate promoter elements that regu-
late PAI-1 transcription and may be responsive to
hypoxia, a series of luciferase reporter gene constructs
was generated in a pGL3 basic vector that represents a
5 deletion of the 5-flanking region of the PAI-1 gene
(Fig. 1B). The resulting chimeric constructs (termed
pGL3PAI.Luc/287, pGL3PAI.Luc/194, pGL3PAI.Luc/
162, and pGL3PAI.Luc/67) were transfected into
RAW264.7 cells to measure their transcriptional activi-
ties. When exposed to hypoxia for 16 h, RAW cells
transfected with pGL3PAI.Luc/162, pGL3PAI.Luc/194
and pGL3PAI.Luc/287 plasmids demonstrated in-
creased transcriptional activity of the PAI-1 promoter
(3.64-fold, P0.001; 7.04-fold, P0.001; and 9.54-fold,
P0.001, respectively, compared with normoxic con-
trols) (Fig. 1B). In contrast, hypoxia did not induce
luciferase activity in RAW cells transfected with
pGL3PAI.Luc/67 plasmids compared with RAW cells
transfected with the same plasmid but incubated in
normoxic conditions. These data indicate that hypoxia
controls PAI-1 transcription in RAW cells by its effects
on a segment of the 5-flanking DNA located between
–287 and –67 upstream of the transcription start site of
PAI-1.
To predict the hypoxia-activated transcription factors
binding sites between –287 and –67 upstream of the
transcription start site of the mouse PAI-1 gene, we
searched for sequences similar to known transcription
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factor binding sequences. This search revealed multiple
potential transcription factor binding sequences, in-
cluding an early growth response (Egr) binding site in
the –137/–129 region and a CCAAT enhancer binding
protein (C/EBP alpha) binding sites in the –209/–200
region of the PAI-1 promoter (Fig. 1A). Two potential
HREs that might bind HIF-1 are present in the –182/
–178 and –171/–167 region of the PAI-1 promoter. The
first potential HIF-1 binding element (which we desig-
nated HRE-1) –182/–178 5-CACGTACA-3matches the
core HIF-1 binding sequence 5-RCGTG-3 (48) (with
RA/G) in 5 of 5 base pairs. The second potential
HIF-1 binding element (designated HRE-2; –171/–167)
5-CACGTGTC-3 also matches the HIF-1 consensus site
in five of five base pairs (Fig. 1A). Each hypoxia-
responsive motif has been implicated in hypoxic up-
regulation of other target genes under different condi-
tions.
To determine whether the Egr, HRE1, HRE2, and
C/EBP binding sites are functionally important for
inducing PAI-1 transcription by hypoxia, we generated
reporter constructs that contained only the C/EBP
(pGLPAI.Luc/CEBP), HER1, and HER2 (pGL-
PAI.Luc/HRE) or EGR (pGLPAI.Luc/EGR) binding
site (Fig. 1B). After exposure to hypoxia for 16 h the
luciferase activity was increased in RAW cells trans-
fected with pGLPAI.Luc/CEBP (3.39-fold, P0.0019),
pGLPAI.Luc/HRE (5.29-fold, P0.001), and pGL-
PAI.Luc/EGR (4.44-fold, P0.001) compared with nor-
moxic controls (Fig. 1B). We also generated reporter
constructs from the –287/50 DNA segment that con-
tained mutated Egr, HRE1, HRE2, and/or C/EBP
binding sites (Fig. 2). As a control, a wild-type (WT) 345
bp construct (pGLPAI.Luc/287) was used. After expo-
sure to hypoxia for 16 h, the RAW cells transfected with
mutant Egr site (pGLPAI.Luc/Emut), mutant HRE-1
and-2 sites (pGLPAI.Luc/Hmut), or mutant C/EBP
site (pGLPAI.Luc/Cmut) constructs elicited a 48%
(P0.001), 80% (P0.001), or 44% (P0.001) de-
crease in transcriptional activity, respectively, com-
pared with WT constructs. RAW cells transfected with
the double mutant Egr and C/EBP [construct desig-
nated pGLPAI.Luc/ECmut], triple mutant Egr, HRE-1,
and HRE-2 [construct designated pGLPAI.Luc/EH-
mut], or triple mutant C/EBP and, HRE-1 and HRE-2
[construct designated pGLPAI.Luc/CHmut] reduced
luciferase activity 64% (P0.001), 79% (P0.001), or
72% (P0.001) compared with WT controls. RAW cells
transfected with mutant constructs at each of the four
sites (Egr, C/EBP, HRE-1, and HRE-2) [construct
designated pGLPAI.Luc/EHCmut] demonstrated an
88% reduction of luciferase activity (P0.001 com-
pared with WT controls; Fig. 2). Note that when all of
these sites were mutated, the hypoxic response was
completely lost. These data suggest that all of the Egr,
HRE-1, HRE-2, and C/EBP binding sites within the
PAI-1 promoter play important roles in the transcrip-
tional activation of PAI-1 expression by hypoxia.
To further characterize the functional significance of
the Egr, HRE-1, HRE-2, and C/EBP binding sites and
the transcription factors that bind to them, EMSAs were
performed on nuclear extracts from RAW cells exposed
to hypoxia or normoxia. For these studies, synthetic
26-mer Egr (–151/–127), 39-mer Hif-1 (–189/–151),
and 27-mer C/EBP (–220/–193) probes were con-
structed based on the nucleotide sequence from the
–287/50 construct we had cloned from the 5-flank-
ing region of the murine PAI-1 gene (sequences for
these probes are found in Materials and Methods).
Binding of nuclear proteins to the various promoter
elements was evaluated under hypoxic and normoxic
conditions.
Egr-1 binds to the mPAI-1 promoter
Nuclear proteins extracted from RAW cells cultured
under hypoxia or normoxia for 30 min, 45 min, or 1 h
were incubated with 32P-labeled Egr probe for 30 min at
room temperature; 45 min hypoxic exposure induced
at least a 5-fold increase in the intensity of a band
corresponding to retardation of the labeled Egr probe
compared with normoxic control. The intensity of the
bands corresponding to retardation of Egr probe was
less strongly induced in RAW cell nuclear extracts
exposed to hypoxia for 1 or 2 h (Fig. 3A, lanes 3–7).
Competition experiments performed by preincubation
with excess unlabeled probe confirmed the specificity
of the radiolabeled Egr probe because the signal was
completely lost. Addition of antibody against murine
Egr-1 to the nuclear extract resulted in further retarded
migration of the radiolabeled band. This supershifting
confirms identity of the protein that interacts with the
DNA as being Egr-1 (Fig. 3A). Western blot analysis of
nuclear Egr-1 protein levels reveals a time course that
closely matches that of the DNA binding activity seen
with EMSA (Fig. 3B).
HIF-1 binds to the mPAI-1 promoter
Nuclear proteins were extracted from RAW cells cul-
tured under 1% O2 or normoxia for 1, 2, 6, or 16 h. The
extracts were incubated for 30 min at 4°C with 32P-
labeled HRE-1/2 probe, which encompassed both the
HRE-1 and HRE-2 sites (Fig. 4A). The onset of HIF-1
HRE-1/2 probe binding is readily apparent 1 h after
placing cells in 1% oxygen. In this time course experi-
ment, binding of the HRE-1/2 probe is greatest after
6 h of 1% oxygen exposure (Fig. 4A). Competition
experiments performed by preincubation with excess
unlabeled probe confirmed the specificity of the radio-
labeled HRE-1/2 probe, because the signal was com-
pletely lost. Addition of antibody against murine
HIF-1 to the nuclear extract resulted in further re-
tarded migration of the radiolabeled band. This super-
shifting confirms identity of the protein that interacts
with the DNA as being HIF-1 (Fig. 4A). Western blot
analysis of nuclear HIF-1 protein levels reveals a time
course that closely matches that of the DNA binding
activity seen with EMSA (Fig. 4B).
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C/EBP binds to the mPAI-1 promoter
To demonstrate a functional effect of C/EBP on
mPAI-1 promoter activity, we performed EMSA using
RAW cell nuclear extracts incubated with 32P-labeled
double-stranded oligonucleotide consisting of a C/EBP
probe, whose sequence encompasses a putative C/EBP
binding site in the 5-flanking region of the mouse
PAI-1 gene (see Materials and Methods for sequence).
Compared with normoxia, higher C/EBP binding ac-
tivity was detected by EMSA in RAW cell nuclear
extracts (Fig. 5A). Labeled C/EBP probe showed a
higher level of binding activity with nuclear extracts
from RAW cells that had been subjected to a hypoxic
environment for 1, 2, 6, or 16 h compared with
comparable nuclear extracts from RAW cell kept in a
normoxic environment for the same period. The DNA
binding was specific since it was efficiently suppressed
by the addition of 100-fold molar excess of the unla-
beled WT C/EBP probe. Preincubation of nuclear
extracts with specific antibodies to C/EBP resulted in
partial supershifting of binding complexes (Fig. 5A).
These data suggest that the C/EBP probe binds specif-
ically to activated C/EBP. Western blot analysis of
nuclear C/EBP protein levels reveals similar hypoxia-
driven increases C/EBP as seen in the EMSA experi-
ments (Fig. 5B).
Figure 4. Effect of hypoxia on HIF-1 DNA binding and
protein expression. A) Effect of hypoxia on the PAI-1 pro-
moter HRE binding motifs. RAW cells were exposed to
normoxia (N) or hypoxia (H) for the indicated times (lanes
1–8). Nuclear extracts were prepared and EMSA was per-
formed using 32P-labeled HIF-1 probe (–189/–151 of PAI-1
promoter). Each lane received 10 g/lane of total nuclear
extract protein. A 100-fold excess of the indicated unlabeled
(cold) HIF-1 probe was added (lane 9). For supershift
analysis, anti-HIF-1 IgG (lane 10) was added. B) Western blot
analyses were performed on nuclear extracts from RAW cells
exposed to hypoxia or normoxia using the same time course
as for the EMSA of HIF-1.
Figure 3. Effect of hypoxia on Egr-1 DNA binding and protein
expression[b]. A) EMSA of the Egr-1 binding to the PAI-1
promoter. RAW cells were exposed to normoxia (lane 3),
hypoxia (H) for 30 min, 45 min, 1 h, or 2 h (lanes 4, 5, 6, or
7 respectively). Nuclear extracts were prepared and EMSA
was performed using 32P-labeled Egr-1 probe (–151/–127 of
PAI-1 promoter). Each lane received 10 g/lane of total
nuclear extract protein. A 100-fold excess of the indicated
unlabeled (cold) Egr-1 probe was added (lane 2). For super-
shift analysis, anti-Egr-1 IgG (lane 8) was added. B) Western
blot analysis was performed on nuclear extracts from RAW
cells exposed to normoxia (lane 1) or hypoxia for 30 min, 45
min, 1 h, or 2 h (lanes 2, 3, 4, or 5, respectively).
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Egr-1, HIF-1, and C/EBP bind to the mPAI-1
promoter in chromatin
To demonstrate that Egr-1, HIF-1, and C/EBP can
bind to the mouse PAI-1 promoter in a macrophage
chromatin environment, chromatin immunoprecipita-
tion assays were performed using RAW cells. RAW cells
were incubated in hypoxia or normoxia for 40 min (for
Egr-1), 2 h (for C/EBP), or 6 h (for HIF-1). Cross-
linked RAW cell lysates were immunoprecipitated with
anti-Egr-1, anti-HIF-1, or anti-C/EBP antibodies and
PCR was used to amplify a 333 bp fragment of mouse
PAI-1 promoter (–220 to 123). These data show that
Egr-1, HIF-1, and C/EBP bind to the mouse PAI-1
promoter only in hypoxic RAW cell chromatin (Fig. 6,
lane 7) but not that of normoxic cells (Fig. 6, lane 4).
These results confirm the gel shift assay results and
indicate that the transcriptional increase in PAI-1 seen
in hypoxic RAW cells is associated with the interaction
of Egr-1, HIF-1, and C/EBP with the PAI-1 promoter.
Effect of overexpression of Egr-1, HIF-1, and C/
EBP on mPAI-1 expression in macrophages
Transient overexpression of Egr-1, HIF-1, and
C/EBP was used to increase PAI-1 transcription in
hypoxic RAW cells. The cells were transiently trans-
fected with pEgr-1, pHIF-1, pC/EBP overexpression
constructs or control vectors. While incubating the
transfected cells in hypoxia or normoxia, cells trans-
fected with pC/EBP or pMT were simultaneously
incubated with 50 M of ZnCl2 to induce C/EBP
protein expression. Total RNA was extracted, followed
by reverse transcription, and quantitative PCR analysis
was performed to evaluate the expression of PAI-1 and
Egr-1, HIF-1, or C/EBP mRNA (Fig. 7, Fig. 8, Fig. 9).
To determine the effect of Egr-1 overexpression on
PAI-1 mRNA transcription, nontransfected control cells
or those cells transfected with pEgr-1 or control vector
were placed in hypoxia or normoxia for 2 h before
PAI-1 mRNA analysis. The expression of PAI-1 mRNA
was increased 2-fold in pEgr-1-transfected hypoxic cells
compared with hypoxic cells transfected with control
vector (P0.001) or nontransfected controls (P0.001)
(Fig. 7A). PAI-1 mRNA expression also increased in
normoxic pEgr-1-transfected cells compared with nor-
moxic control vector-transfected cells (5-fold increased,
P0.001) and nontransfected cells (6-fold increased,
P0.001) (Fig. 7B). In pEgr-1-transfected cells, Egr-1
mRNA expression was increased  1000-fold compared
with controls (P0.001) (Fig. 7B). These data show that
1) transfection of the Egr-1 containing vector increases
PAI-I-1 expression under all conditions, and 2) hypoxia
Figure 6. Chromatin immunoprecipitation of Egr-1, HIF1,
and C/EBP interaction with PAI-1 promoter in RAW cells.
Bands indicate PCR products targeting –220 to 130 of PAI-1
promoter. RAW cells were exposed to hypoxia or normoxia
for the time indicated. 5 g of anti-Egr-1, anti-HIF-1, or
anti-C/EBP antibodies (lane 7 for hypoxia, lane 4 for
normoxia). 5 g of rabbit IgG (lane 5 for hypoxia), no
antibody (lane 6 for hypoxia, lane 3 for normoxia), and
1/100 of input (lane 2 for hypoxia, lane 1 for normoxia) were
applied to the PCR reaction, respectively.
Figure 5. Effect of hypoxia on C/EBP DNA binding and
protein expression. A) Effect of hypoxia on the C/EBP
binding motif in the PAI-1 promoter. RAW cells were exposed
to normoxia (N) or hypoxia (H) for the times indicated
(lanes 1–8). Nuclear extracts were prepared and EMSA was
performed using 32P-labeled C/EBP probe (–220/–193 of
PAI-1 promoter). Each lane received 10 g/lane of total
nuclear extract protein. A 100-fold excess of the indicated
unlabeled (cold) C/EBP probe was added (lane 9). For
supershift analysis, anti-C/EBP IgG (lane 11) was added. B)
Western blot analyses were performed on nuclear extracts of
RAW cells exposed to hypoxia or normoxia for the same time
course as for the EMSA of C/EBP.
942 Vol. 21 March 2007 LIAO ET AL.The FASEB Journal
augments PAI-1 expression in the Egr-1 transfectants
more than the normoxic Egr-1 transfectants.
To determine the effect of HIF-1 overexpression on
PAI-1 mRNA transcription, nontransfected control cells
or those cells transfected with pHIF-1 or control
vector were placed in hypoxia or normoxia for 6 h
before PAI-1 mRNA analysis. The expression of PAI-1
mRNA was increased 48% in pHIF-1-transfected
hypoxic cells compared with hypoxic cells that were
transfected only with contro1 vector (P0.05) and
nontransfected controls (P0.05) (Fig. 8A). The
HIF-1 mRNA expression in pHIF-1-transfected cells
was increased by 1000-fold compared with controls
(P0.001) (Fig. 8B). These data show that 1) transfec-
tion of the HIF-1-containing vector increases PAI-1
expression under all conditions, and 2) hypoxia aug-
ments PAI-1 expression in the HIF-1 transfectants
more than the normoxic HIF-1 transfectants. There is
some increase in PAI-1 expression in the HIF-1 nor-
moxic conditions, which may be due to the degradative
pathways in the transfectants being overwhelmed.
To determine the effect of C/EBP overexpression
on PAI-1 mRNA transcription, nontransfected control
cells or those cells transfected with pC/EBP or control
vector were placed in hypoxia or normoxia for 2 h (with
50 M ZnCl2 to induce expression of C/EBP) before
PAI-1 mRNA analysis. This resulted in an increase of
mouse PAI-1 mRNA expression by 1.8-fold in pC/
EBP-transfected hypoxic cells compared with either
hypoxic cells transfected with pMT (empty) vector
(P0.001) or nontransfected controls (P0.001) (Fig.
9A). The PAI-1 mRNA expression also increased 3-fold
in normoxic pC/EBP-transfected cells compared with
pMT vector-transfected cells (P0.001) and 4-fold com-
pared with nontransfected cells (P0.001) (Fig. 9A). In
pC/EBP-transfected cells, C/EBP mRNA expression
was increased 1000-fold compared with controls
(P0.001) (Fig. 9B). These data show that 1) transfec-
tion of the C/EBP-containing vector increases PAI-1
expression under all conditions, and 2) that hypoxia
Figure 8. Effect of overexpression of HIF-1 on PAI-1 mRNA
expression on RAW cells. RAW cells were transfected with
HIF-1 overexpression plasmid or empty pcDNA3.1 vector.
24 h after transfection, the cells were exposed to hypoxia or
normoxia for 6 h. Total RNA was extracted and the relative
quantity of mPAI-1 mRNA (A) and HIF-1 mRNA (B) was
measured.
Figure 7. Effect of overexpression of Egr-1 on PAI-1 mRNA
expression on RAW cells. RAW cells were transfected with
Egr-1 overexpression plasmid or empty pcDNA3.1 vector.
24 h after transfection cells were exposed to hypoxia or
normoxia for 40 min, then total RNA was extracted and the
relative quantity of mPAI-1 mRNA (A) and Egr-1 mRNA (B)
was measured.
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augments PAI-1 expression in the C/EBP transfec-
tants more than the normoxic C/EBP transfectants.
Egr-1, HIF-1, and C/EBP overexpression enhanced
the activation of the mPAI-1 promoter in hypoxia
RAW cells were cotransfected with a luciferase reporter
plasmid (pGL3PAI.Luc/287, or pGL3 basic control
vector), a pCMV/-galactosidase vector, and three
overexpression constructs. The transient transfections
of overexpression constructs consisted of the following
plasmid combination (as indicated in (Fig. 10): empty
control vectors (pcDNA3.1 or pMT) and/or specific
overexpression constructs (pEgr-1, pHIF-1, and/or
pC/EBP) to total transfection of 2 g of DNA. Trans-
fected cells were incubated in hypoxia or normoxia
with 10 M of ZnCl2 for 16 h. Firefly luciferase activity
of the cell lysates was then measured and normalized by
control pCMV/-galactosidase activity (Fig. 10). These
data show that, in hypoxia, in cells transfected with
pGL3PAI.Luc/287, luciferase activity of RAW cells also
transfected with pEgr-1, pHIF-1, or p/CEBP was
increased 68% (P0.01), 170% (P0.001), or 43%
(P0.05) compared with their respective control trans-
fectants. pGL3PAI.Luc/287-transfected cells cotrans-
fected with pEgr-1 and pHIF-1 had a 90% increase
compared with cells transfected with pEgr-1 only
(P0.001) and an 18% increase compared with
pHIF-1 transfectants (P0.05). pGL3PAI.Luc/287-
transfected cells cotransfected with pEgr-1 and pC/
EBP had a 32% increase compared with cells trans-
fected with pEgr-1 only (P0.05) and an 54% increase
compared with pC/EBP transfectants (P0.001).
pGL3PAI.Luc/287-transfected cells cotransfected with
pHIF-1 and pC/EBP had a 27% increase compared
with cells transfected with pHIF-1 only (P0.001) and
an 139% increase compared with pC/EBP transfec-
tants (P0.001). pGL3PAI.Luc/287-transfected cells,
cotransfected with pEgr-1, pHIF-1, and pC/EBP had
a 188% increase compared with cells transfected with
pEgr-1 only (P0.001), a 78% increase compared with
pHIF-1 only (P0.001), a 236% increase compared
with pC/EBP only (P0.001), a 51% increase com-
pared with pEgr-1 and pHIF-1 (P0.001), an 118%
increase compared with pEgr-1 and pC/EBP
(P0.001), and a 41% increase compared with pHIF-1
Figure 10. Egr-1, HIF-1, and C/EBP overexpression en-
hanced activation of the mPAI-1 promoter in hypoxic RAW
cells cotransfected with 0.25 g of luciferase reporter plasmid
(pGL3PAI.Luc/287 or pGL3 basic control vector), 0.5 g of
pCMV/-galactosidase, and a combination of the three over-
expression constructs or controls (0.25 g of each construct):
empty control vectors (pcDNA3.1, or pMT) and/or specific
overexpression constructs (pEgr-1, pHIF-1, and/or pC/
EBP). The transfection mixture consisted of specific over-
expression constructs with the balance comprised of the
appropriate control vectors. These mixtures were used to
equalize the total amount of DNA transfected in each well.
Transfected cells were incubated in hypoxia or normoxia with
10 M of ZnCl2 for 16 h. Firefly luciferase activities of the cell
lysates were then measured by the same procedure as de-
scribed in Fig. 1 and normalized by control pCMV/-galac-
tosidase activity.
Figure 9. Effect of overexpression of C/EBP on PAI-1 mRNA
expression on RAW cells. RAW cells were transfected with
C/EBP overexpression plasmid or empty pMT vector. 24 h
after transfection the cells were exposed to hypoxia or
normoxia for 2 h and simultaneously incubated with 50 M of
ZnCl2 to induce C/EBP expression. Total RNA was ex-
tracted and the relative quantity of mPAI-1 mRNA (A) and
C/EBP mRNA (B) was measured.
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and pC/EBP transfectants (P0.001) (Fig. 10). These
data showed that in hypoxia, luciferase activity was
significantly increased in RAW cells cotransfected with
two overexpression plasmids compared with cells trans-
fected with only one overexpression construct. Further,
luciferase activity was increased significantly in the
RAW cells cotransfected with three overexpression plas-
mids compared with cells transfected with either two or
one overexpression construct.
To verify that the Egr-1-, HIF-1-, or C/EBP-driven
PAI-1 mRNA expression seen in RAW cells was not cell
line dependent, the murine peritoneal macrophages
were isolated and transfected with pEgr-1, pHIF-1, or
C/EBP. While incubated in hypoxia or normoxia for
4 h, the cells transfected with C/EBP or pMT empty
control vector were simultaneously treated with 50 M
ZnCl2 to induce expression of C/EBP protein. The
total RNA was then isolated and RT-qPCR was per-
formed to measure the mRNA levels of PAI-1, Egr-1,
HIF-1, or C/EBP mRNA. The results show that the
expression of PAI-1 mRNA was increased by 75% in
pEgr-1-transfected hypoxic cells compared with
hypoxic cells transfected with control vector (P0.01)
or nontransfected controls (P0.05) (Fig. 11A). PAI-1
mRNA expression also increased in normoxic pEgr-1-
transfected cells compared with normoxic control vec-
tor-transfected cells (40% increase, P0.05) and non-
transfected cells (1.9-fold increase, P0.01) (Fig. 11A).
In pEgr-1-transfected cells, Egr-1 mRNA expression was
increased 1000-fold compared with controls (P0.001)
(Fig. 11B). PAI-1 mRNA expression was increased 3.2-fold
in pHIF-1-transfected hypoxic cells compared with
hypoxic cells transfected with control vector (P0.001)
or nontransfected controls (P0.001) (Fig. 12A). The
HIF-1 mRNA expression in pHIF-1-transfected mu-
rine peritoneal macrophages was  100-fold increased
compared with controls (P0.001) (Fig. 12B). The
expression of PAI-1 mRNA was increased 1.2-fold in
pC/EBP-transfected hypoxic cells compared with the
hypoxic cells transfected with control vector (P0.001)
or nontransfected controls (P0.001) (Fig. 13A). In
pC/EBP-transfected murine peritoneal macrophages,
C/EBP mRNA expression was increased 100-fold
compared with controls (P0.001) (Fig. 13B). These
data confirm results from the overexpression plasmid-
transfected murine peritoneal macrophages that 1)
transfection of the Egr-1, HIF-1 or C/EBP-contain-
ing vector increases PAI-1 expression under all condi-
tions, and 2) hypoxia augments PAI-1 expression in the
Egr-1, HIF-1, or C/EBP transfectants more than the
normoxic transfectants.
DISCUSSION
When cells are deprived of oxygen, genetically pro-
grammed responses either help them to adapt or, in
certain instances, lead to pathological responses and
tissue injury. Because of the crucial role of oxygen as
life itself evolved, organisms have developed a number
of highly conserved mechanisms to regulate the cellular
response to low oxygen tension. In addition to energy
conservation strategies, hypoxia leads cells of the vessel
wall to undergo phenotypic shifts such that inflamma-
tory and thrombotic mechanisms dominate the intra-
vascular milieu. One of the most tightly regulated
responses to periods of oxygen deprivation, inflamma-
tion, or ischemia is that governing the expression of a
key regulator of fibrinolysis, plasminogen activator in-
hibitor-1 (PAI-1). PAI-1 is a 50 kDa serine protease
inhibitor (SERPIN) that is the major inhibitor of fibri-
nolysis. It binds avidly to plasminogen activators (PAs),
inhibiting their lytic action on fibrinogen. PAI-1 is
strongly induced by vascular cells exposed to conditions
of inflammation, hypoxia, or ischemia, which results in
the suppression of fibrinolysis and hence the accrual of
fibrin. It is likely that the mechanism(s) underlying
hypoxic induction of PAI-1 have been highly conserved
over evolutionary time because fibrin accumulation
provides the stromal matrix to support the ingrowth of
new blood vessels into an oxygen-scarce environment.
Our group reported in 1998 that hypoxia elicits a
Figure 11. Effect of overexpression of Egr-1 on PAI-1 mRNA
expression on peritoneal macrophages. The primary macro-
phages were transfected with Egr-1 overexpression plasmid or
empty pcDNA3.1 vector. 24 h after transfection the cells were
exposed to hypoxia or normoxia for 4 h. Total RNA was
extracted and the relative quantity of mPAI-1 mRNA (A) and
Egr-1 mRNA (B) were measured.
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brisk and profound increase in PAI-1 mRNA levels and
protein expression, and concomitant evidence for tis-
sue thrombosis. Nuclear run-on analysis demonstrated
that the increase in PAI-1 mRNA levels is largely driven
by increases in transcription, yet the underlying factors
driving the increased transcription of the PAI-1 gene
under hypoxic conditions were not identified. In the
current work, mechanisms underlying transcriptional
activation of the PAI-1 gene by hypoxia are elucidated.
These data show that the transcription factors Egr-1,
HIF-1, and C/EBP each contribute to mouse PAI-1
gene transcription, independently and potentially co-
operatively.
Early growth response gene-1 (Egr-1) is a zinc finger
transcription factor recently dubbed a “master switch,”
which regulates the coordinated cellular response to
oxygen deprivation (49). When mononuclear phago-
cytes are placed in a hypoxic environment, a cascade of
events is triggered (19), leading to the rapid induction
of Egr-1. Similarly, when a tissue (the lungs) was subject
to an abrupt interruption of blood flow secondary to
placement of a ligature around its arterial blood supply,
there was a profound (12-fold) increase in PAI-1
mRNA levels at 4 h. However, when mice null for the
Egr-1 gene were subjected to similar ischemic proce-
dures, there was a significant dampening of the incre-
ment of PAI-1 expression (only a 3-fold increase)
(49). These data support our previous observation that
PAI-1 expression is strongly inducible by hypoxia (5),
and indicate that Egr-1 plays an important although not
exclusive role in the ischemic induction of this protein.
Data presented here show that the 5-flanking DNA
promoter region of the murine PAI-1 gene (from –162
to 50) [overlapping the PAI-1 start codon] is respon-
sible in part, for the appearance of PAI-1 transcripts in
mononuclear phagocytes after hypoxic exposure com-
mences. This region encompasses a critical Egr-1 site
(from –137 to –129), implicating Egr-1 as a driver of
hypoxic induction of PAI-1 gene transcription. Func-
tional analysis performed using Egr-1 cDNA overex-
Figure 13. Effect of overexpression of C/EBP on PAI-1
mRNA expression on peritoneal macrophages. Primary mac-
rophages were transfected with C/EBP overexpression plas-
mid or empty pMT vector. 24 h after transfection, cells were
exposed to hypoxia or normoxia for 4 h and simultaneously
incubated with 50 M of ZnCl2 to induce C/EBP expres-
sion. Total RNA was extracted and the relative quantity of
mPAI-1 mRNA (A) and C/EBP mRNA (B) was measured.
Figure 12. Effect of overexpression of HIF-1 on PAI-1 mRNA
expression on peritoneal macrophages. The primary macro-
phages were transfected with HIF-1 overexpression plasmid
or empty pcDNA3.1 vector. 24 h after transfection the cells
were exposed to hypoxia or normoxia for 4 h. Total RNA was
extracted and the relative quantity of mPAI-1 mRNA (A) and
HIF-1 mRNA (B) was measured.
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pression to increase PAI-1 transcription in both RAW
and murine peritoneal cells, gel mobility shift assays,
chromatin immunoprecipitation assays, as well as im-
munoblot analysis of nuclear protein extracts for Egr-1,
demonstrate an extremely brisk Egr-1 response to hyp-
oxia, with increased Egr-1/DNA binding as early as 30
min after hypoxic exposure. Mutation of the Egr pro-
moter site partially abolishes the hypoxic response,
proving that it is actually the Egr-1 site responsible for
the inductive response of the PAI-1 gene to hypoxia.
Though the Egr-1-driven response of PAI-1 to hyp-
oxia is robust, it is by no means exclusive. Hypoxia-
driven expression of PAI-1 transcripts appears to be
affected by alternative mechanisms as well, including
HIF-1 and C/EBP- transcriptional mechanisms (see
below). Nevertheless, even when these alternative sites
are abolished (i.e., use of promoter-reporter constructs
retaining the Egr site but in which the promoter region
encompassing HIF-1 and c/EBP- sites as been deleted
and the Egr site ligated directly to the –62 to 50
flanking region), the Egr site still retains some hypoxic
response.
HIF-1 is recognized to be a key transcription factor
responsible for oxygen regulation of several genes such
as erythropoietin, VEGF, inducible NOS, and PAI-1
(50–53). In these and other experiments, HIF-1 DNA
binding activity, a functional laboratory marker for the
presence of HIF-1 protein, is detected in nuclear ex-
tracts derived from cells grown under hypoxic condi-
tions; it is undetectable under normoxic conditions.
Both HIF-1 mRNA and protein are ubiquitously ex-
pressed in all organs of human and rodents (54), both
are rapidly induced by hypoxia, and both rapidly decay
upon return to normoxic conditions (26, 55–57). The
murine PAI-1 promoter region (–182/–167) contains
two potential E-box sequences, 5-CANNTG-3 (58)
[5-CACGTG-3 (–172/–167) and the reverse comple-
ment 5-CACGTA-3 (–182/–177)], named HRE-1 and
HRE-2, respectively. E-box sequences comprise an up-
stream regulatory region that controls transcription of
a variety of genes involved with cell development,
differentiation, growth, and neoplasia. Typically, tran-
scription factors containing a common basic helix-loop-
helix (bHLH) motif (with or without a leucine zipper)
bind to the E-box sequence to activate transcription.
HIF-1 is an example of a bHLH-PAS protein that binds
to E-box sequences, found in the promoter regions of a
variety of genes, which confer hypoxia sensitivity.
Induction of PAI-1 gene expression by hypoxia was
shown to depend on both HRE-1 and HRE-2 motifs in
the PAI-1 promoter (59). However, no other driving
motifs responsive to hypoxia were identified in that
work. In the work presented here, we have shown that
these HREs play an important, though not exclusive,
role in hypoxic induction of PAI-1 gene transcription.
Under hypoxic conditions, the HIF-1 protein is stabi-
lized (57) and transported into the nucleus (60),
leading to accumulation of the active HIF-1/HIF-1
heterodimer. The active HIF-1 heterodimer that accu-
mulates under conditions of oxygen scarcity leads to
the induction of PAI-1 gene expression. Similarly, we
showed that a transient overexpression of HIF-1 is
able to induce PAI-1 gene expression in RAW and
peritoneal macrophages. In our study, we have shown
that HIF-1 is just one important regulator driving
ischemic induction of PAI-1 protein.
The third promoter sequence that we identified as
exhibiting hypoxic sensitivity was C/EBP. This is the
first demonstration of the role of this promoter ele-
ment in the hypoxic regulation of gene expression. The
activity and/or expression level of the three C/EBP
members (, , and ) is regulated by a number of
inflammatory mediators, including lipopolysaccharide
(LPS) and an array of cytokines (61–65). C/EBP is
known to play an important role in mediating the
acute-phase response; for instance, IL-1 induces
C/EBP expression in neonatal mice’s liver (41). In
our study we have shown that CEB/P is a regulator in
the ischemic induction of PAI-1 protein. After hypoxic
exposure, a promoter construct that only included the
C/EBP site in the upstream regulatory region of the
murine PAI-1 gene increased PAI-1 transcription by
 3-fold. A promoter construct that retains only the
intact C/EBP site, but has the Egr and other HREs
mutated similarly demonstrated an 3-fold induction
by hypoxia. On the other hand, mutation of the C/EBP
site diminished (by 40%) induction of the PAI-1 gene
in response to hypoxia, compared with similar hypoxic
conditions in an intact WT C/EBP sequence. Finally,
direct overexpression of C/EBP is able to induce
PAI-1 gene expression in RAW and peritoneal macro-
phages.
Taken together, these data are the first to demon-
strate that PAI-1 transcription induced by hypoxia
represents a complex interplay between various pro-
moter elements of the gene. When working in concert,
the combination of all four promoter regions (1 Egr, 2
HREs, and CEB/P) produces the strongest inductive
response to hypoxic conditions. Our data clearly show
that the promoter region studied dominates the
hypoxic response as its truncation nearly abrogates
hypoxia-driven increases in PAI-1 transcription. Never-
theless, the minor residual hypoxic response could very
well have been driven by other genetic elements lo-
cated outside the region of study. There is also the
possibility that full-length gene studies could identify
additional regulatory regions. One can imagine a ho-
meostatic mechanism whereby various elements in the
PAI-1 promoter gene might be involved in coordina-
tion, enhancement, or fine-tuning of PAI-1 gene ex-
pression under various levels or durations of hypoxic
exposure. The clinical response to ischemia, typified by
PAI-1 induction as a means for promoting thrombus
accrual, is redundant and highly regulated, as would be
expected for an important physiological or adaptive
response to oxygen deprivation.
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